ライフサイエンスコーパス: ALT

1 ALT activity was low, which was likely due to underlying

2 ALT and AST values were significantly higher in males th

3 ALT cells exhibited preferential elongation of the telom

4 ALT cutoffs for screening were based on local reference

5 ALT is enriched in tumors of mesenchymal origin, includi

6 ALT is expressed antisense to the major viral latency tr

7 ALT is mediated by recombination and is prevalent in a s

8 ALT levels were positively associated with GDM risk with

9 ALT relies on exchanges of telomeric DNA to maintain tel

10 ALT was detected in epidermal stem cells in Terc(-/-) mi

11 ALT, AST, and GGT correlated with BMI, CRP and HbA1c and

12 ALT-803 is an IL-15 superagonist complex that has been d

13 ALT-activity assays may be compromised with co-existing

14 ALT-associated replication defects trigger mitotic DNA s

15 subjects (79%) experienced either grade >/=1 ALT or AST elevation during the study, and 13 subjects (

16 showed that body mass index >/= 27 kg/m(2), ALT level >/=3 times the upper limit of normal, aspartat

17 s, and one dose-limiting toxicity of grade 3 ALT elevation was observed at 12 mg daily.

18 Grade 3-4 ALT elevations during the study period were rare but mor

19 turase-associated biomarkers (CRP, fetuin-A, ALT, and GGT) did not lead to appreciable attenuations.

20 BMI > 25 kg/m(2) and 1382 (44%) had abnormal ALT.

21 ted telomerase positive cells do not acquire ALT-like phenotypes.

22 ients primed with the IL-15 receptor agonist ALT-803 in vivo displayed enhanced ex vivo functional re

23 onally, we found that a human IL-15 agonist (ALT-803) improved airway resistance and compliance in an

24 ormal human epidermal keratinocytes are also ALT-positive.

25 netic instrument (F-statistic = 23) for ALT, ALT levels were negatively associated with IHD (odds rat

26 y recording neural responses to alternating (ALT) and synchronous (SYNC) tone sequences in A1 of male

27 y recording neural responses to alternating (ALT) and synchronous (SYNC) tone sequences in macaque A1

28 ry (determined by alanine aminotransaminase [ALT] and cytokeratin-18 [CK-18]).

29 carriers had higher alanine aminotransferase ALT and lower lipid levels (P < 0.05), as well as a lowe

30 fibrinolysis) and alanine aminotransferase (ALT) (marker of ischemia-reperfusion [I/R] injury) were

31 y using ELISA, and alanine aminotransferase (ALT) activity by using a colorimetric assay.

32 tolerance, and the alanine aminotransferase (ALT) activity in these mice returned to normal despite c

33 ed serum levels of alanine aminotransferase (ALT) and liver steatosis and fibrosis, compared with mic

34 adverse events and alanine aminotransferase (ALT) concentrations over 12 weeks, and cardiac events (d

35 ions of persistent alanine aminotransferase (ALT) elevation and associated factors in chronic hepatit

36 ansferase (AST) or alanine aminotransferase (ALT) elevation with fevers, and grade 3 pulmonary infect

37 ast 1 flare in the alanine aminotransferase (ALT) level (>200 U/L; P = .007).

38 ls >2000 IU/mL and alanine aminotransferase (ALT) levels >80 U/mL, respectively.

39 e of jaundice, and alanine aminotransferase (ALT) levels <1.5 times the upper limit of normal.

40 idence of maternal alanine aminotransferase (ALT) levels above two times the upper limit of normal fo

41 on, steatosis, and alanine aminotransferase (ALT) levels and viscoelastic and diffusion parameters.

42 internationally by alanine aminotransferase (ALT) levels equal to or exceeding 5x the upper limit of

43 m lipids and serum alanine aminotransferase (ALT) levels were measured and an abdominal ultrasound wa

44 the association of alanine aminotransferase (ALT) levels with ischaemic heart disease (IHD) and cardi

45 Alanine aminotransferase (ALT) predicts type 2 diabetes but it is uncertain whethe

46 index (FIB-4), AST/alanine aminotransferase (ALT) ratio (AAR), and age-platelet index (API) for signi

47 CatD and alanine aminotransferase (ALT) were measured in plasma.

48 0 IU/mL, and 26.7% alanine aminotransferase (ALT)>/=2x upper limit of normal (>/=40 U/L women, >/=60

49 aminotransferase, alanine aminotransferase (ALT), acute kidney injury (AKI), model for end stage liv

50 the liver enzymes, alanine aminotransferase (ALT), alkaline phosphatase (ALP) and gamma glutamyltrans

51 ally reduced serum alanine aminotransferase (ALT), alkaline phosphatase (AST), total bilirubin (TBIL)

52 transferase (GGT), alanine aminotransferase (ALT), and aspartate aminotransferase (AST), among a disc

53 Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and fetuin-A were

54 Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phospha

55 increases in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phospha

56 Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutam

57 Alanine aminotransferase (ALT), gamma-glutamyltransferase (GGT) and direct bilirub

58 T, >49.9 IU/L) and alanine aminotransferase (ALT, >56.1 IU/L), to the relationships of HBV and HCV in

59 -3.36; P < 0.001), alanine aminotransferase (ALT; OR, 1.24; 95% CI: 1.12-1.38; P < 0.001), smoking (O

60 ed serum levels of alanine-aminotransferase (ALT), liver histology, hepatic triglyceride content (HTC

61 e standard course (alanine aminotransferase [ALT] activity >100 U/L).

62 esumed NAFLD (pNF; alanine aminotransferase [ALT] level >/= 20 for women or >/= 31 for men and body m

63 nsferase [AST] and alanine aminotransferase [ALT]) are usually increased in patients with nonalcoholi

64 platelet x radical alanine aminotransferase [ALT]).

65 levation of serum alanine aminotransferases (ALT) (>45 U/l).

66 An ALT >165 IU/L produced 72% sensitivity and 55% specifici

67 rechallenge has recently been defined by an ALT level of 3-5x ULN or greater.

68 was only a slight increase in plasma AST and ALT levels between diseased and healthy states (22.55 ve

69 However, salivary AST and ALT levels showed a approximately 6-fold rise in the pat

70 verity of IR injury as determined by AST and ALT levels, as well as immune cell infiltrates.

71 exhibited only modest elevations of AST and ALT levels.

72 tively correlated with liver enzymes AST and ALT, and negatively correlated with white blood cell cou

73 ol; triglycerides; fasting glucose; AST; and ALT levels were analyzed on a biochemistry analysis syst

74 At the diagnosis, levels of total BA and ALT were higher in the group using UDCA compared to the

75 Only 14% of trials used both BMI and ALT for screening.

76 eactivation, or they can monitor HBV DNA and ALT levels and initiate on-demand antivirals.

77 e patients for reactivation with HBV DNA and ALT levels, promptly starting antivirals if reactivation

78 Inflammation and ALT level were not associated with the viscoelastic or d

79 studies showing association between PFOA and ALT, a marker of hepatocellular damage.

80 limit of normal (ULN) and six times ULN, and ALT concentrations between three and seven times ULN.

81 e vegetation and edaphic characteristics and ALTs across multiple plots in four field sites within bo

82 ng of the anti-human TF monoclonal antibody (ALT-836) with (89)Zr.

83 The four Arabidopsis ALT genes were found to have distinct gene expression pr

84 5N72D.IL-15RalphaSuFc complex, also known as ALT-803, is a multimeric complex constructed by fusing I

85 se survivors exhibit type II-like as well as ALT-like telomere features.

86 gh ratio of aspartate aminotransferase (AST):ALT were independent risk factors for ALF.

87 logic features in the livers, including AST, ALT, and a panel of cytokines and chemokines, were exami

88 levels of hepatobiliary injury markers AST, ALT, LDH, and gamma-GT after 6 hours of NMP.

89 , thrombocytopenia (n = 2), and elevated AST/ALT (n = 1), were observed with schedule A; one dose-lim

90 limiting toxicity was observed (elevated AST/ALT) was observed with schedule B.

91 lia (BV-2)) or more rapidly than (astrocyte (ALT)) Ag (I), the ratio of AgNPs to total Ag (AgNPs+Ag (

92 ically reduces the replication efficiency at ALT telomeres.

93 le difference in TF-binding affinity between ALT-836 and Df-ALT-836 in vitro.

94 estern Blot and liver injury was assessed by ALT and histology.

95 k factors and liver damage, as determined by ALT levels.

96 n adducts were increased at 1 h, followed by ALT increases at 12 and 24 h.

97 th the degree of I/R injury, as reflected by ALT levels.

98 ecreased ECG ALT (-77+/-9%, P<0.05) and Ca2+ ALT (-56+/-7%, P<0.05) and, importantly, reduced ROS (-6

99 In MI, ECG ALT (2.32+/-0.41%) and Ca2+ ALT (22.3+/-4.5%) were significantly greater compared wi

100 treatment had no effect on ECG ALT and Ca2+ ALT.

101 (ECG ALT) and Ca2+ transient alternans (Ca2+ALT) were induced by rapid pacing (300-120 ms) before an

102 To characterize ALT in detail, we physically isolated this lncRNA by a s

103 lly, we demonstrated that, in FANCM-depleted ALT cells, BRCA1 and BLM help to resolve the telomeric r

104 cells and their human TERC knockout-derived ALT human cell lines, we show that ALT cells harbor more

105 ristics, and their interactions in determine ALTs, is currently lacking.

106 n TF-binding affinity between ALT-836 and Df-ALT-836 in vitro.

107 (89)Zr-labeling of Df-ALT-836 was achieved in high yield and good specific act

108 sh the affinity and specificity of (89)Zr-Df-ALT-836 for TF in vivo.

109 e BXPC-3 tumors, PET imaging using (89)Zr-Df-ALT-836 promises to open new avenues for improving futur

110 s unveiled a lasting and prominent (89)Zr-Df-ALT-836 uptake in BXPC-3 tumors (peak at 31.5+/-6.0%ID/g

111 ent affinity and TF-specificity of (89)Zr-Df-ALT-836.

112 n tumor-bearing mice injected with (89)Zr-Df-ALT-836.

113 of recombination recruited by RPA, disrupts ALT and triggers chromosome fragmentation and apoptosis

114 t in the intermolecular exchanges that drive ALT.

115 Upon withdrawing the suspect drug, ALT generally decrease by 50% or more.

116 ECG T-wave alternans (ECG ALT) and Ca2+ transient alternans (Ca2+ALT) were induced

117 atment with ALLO significantly decreased ECG ALT (-77+/-9%, P<0.05) and Ca2+ ALT (-56+/-7%, P<0.05) a

118 In MI, ECG ALT (2.32+/-0.41%) and Ca2+ ALT (22.3+/-4.5%) were signi

119 l antioxidant treatment had no effect on ECG ALT and Ca2+ ALT.

120 increased in patients with NASH and elevated ALT levels (P < 0.0001).

121 ased liver triglyceride content and elevated ALT, bilirubin and alkaline phosphatase due to three hep

122 Patients with NAFLD and elevated ALT, even when well matched for body mass index to those

123 In conclusion, elevated ALT levels in the first trimester even within normal ran

124 eatohepatitis (NASH) with normal or elevated ALT levels.

125 Patients with normal versus elevated ALT had similar severity of NASH, suggesting that plasma

126 er disease mortality was found with elevated ALT (HR, 4.08; 95% CI: 1.99-8.33), AST (HR, 4.33; 95% CI

127 ormal ALT (n = 165); and NAFLD with elevated ALT (n = 215).

128 -related harms were associated with elevated ALT (odds ratio [OR], 1.87; 95% confidence interval [CI]

129 P < 0.0001) were worse in NASH with elevated ALT.

130 rance, or elevated serum levels of estrogen, ALT, and lipids.

131 le genetic instrument (F-statistic = 23) for ALT, ALT levels were negatively associated with IHD (odd

132 nd 340; 294 and 292; and 366 and 321 U/L for ALT and AST, in Vit D, LE and LE + Vit D treated groups,

133 lso suggests that forest fires cause greater ALTs by simultaneously decreasing multiple ecosystem cha

134 ia (OR, 4.13), hypertension (OR, 3.67), high ALT level (OR, 1.86), and family history of diabetes (OR

135 idence intervals): 1.41(1.21-1.65)] and high ALT levels (>/=40 U/L) [1.62 (1.31-2.00)] were associate

136 o estimate additive interaction between high ALT and overweight/obesity for GDM.

137 Increased necroinflammation and higher ALT level were associated with faster progression.

138 <9 months), neonatal cholestasis, and higher ALT levels.

139 Genetically higher ALT was associated with higher risk of diabetes, odds ra

140 at alcohol-fed DEN-injected mice have higher ALT and liver-to-body weight ratio compared to pair-fed

141 t cannot exclude the possibility that higher ALT may protect against CAD/MI.

142 e synthesis, but molecular mechanisms of how ALT maintains telomere length in human cancer is poorly

143 Depletion of FANCD2 results in a hyper-ALT phenotype, including an increase in extrachromosomal

144 reak-induced replication, similar to type II ALT survivors in Saccharomyces cerevisiae Replication st

145 rs chromosome fragmentation and apoptosis in ALT cells.

146 er damage manifested by a marked decrease in ALT, and AST serum levels (from 900 and 1021 U/L in the

147 the most common of which were elevations in ALT (62 [11%] of 577 patients receiving tenofovir alafen

148 and AQ resulted in the greatest increase in ALT (200-300 U/L), and necroinflammatory responses chara

149 The increase in ALT case incidence in the lapatinib arm showed no eviden

150 xposure was associated with a 6% increase in ALT levels (95% CI: 4, 8%) and a 16% increased odds of h

151 CTLA4 also resulted in a greater increase in ALT than treatment with AQ alone; however, these mice al

152 There were significant increases in ALT (p < 0.001) and AST (p = 0.013) with increased fat c

153 onuclei formation and synthetic lethality in ALT cells.

154 recombination-mediated telomere synthesis in ALT cancers.

155 se axis as a potential therapeutic target in ALT tumors.

156 We observe frequent fragile telomeres in ALT cells, suggesting that telomere sequences are prone

157 We propose that, in ALT cells, FANCD2 promotes intramolecular resolution of

158 Surface moisture (0-6 cm) promoted increased ALTs, whereas deeper soil moisture (11-16 cm) acted to m

159 immortalized via the telomerase-independent ALT mechanism.

160 y viral lncRNA, ALT, by physically isolating ALT and by a sequencing-independent assay.

161 joining (C-NHEJ) or alternative end joining (ALT-EJ)], which cause distinct rearrangement junction pa

162 iated in severe ICP (total BA > 40 mumol/l), ALT levels were also significantly higher and ICP was di

163 d the lateral antennal lobe tracts (m- and l-ALT), separately arborizing two antennal lobe hemilobes

164 nd lateral antennal lobe tracts (m-ALT and l-ALT).

165 queen mandibular pheromone is processed by l-ALT (lateral antennal lobe tract) neurons and brood pher

166 t the hypothesis that the lateral pathway (l-ALT) is sufficient for elemental learning, we modelled l

167 ive patterning can be accounted for by the l-ALT model, negative patterning requires further processi

168 w neural layers of odour processing in the l-ALT.

169 nuscript characterizes one key viral lncRNA, ALT, by physically isolating ALT and by a sequencing-ind

170 children with late-onset presentation, lower ALT, and intracellular BSEP expression are likely to res

171 and brood pheromone is mainly processed by m-ALT (median antennal lobe tract) neurons, worker pheromo

172 with a reward signal even after lesions in m-ALT or blocking the mushroom bodies.

173 d medial and lateral antennal lobe tracts (m-ALT and l-ALT).

174 itivity at 6 months and ameliorated maternal ALT elevations.

175 Importantly ATRX-mediated ALT suppression is dependent on the histone chaperone DA

176 GGT were not clearly associated with CAD/MI (ALT OR 0.74, 95% CI 0.54 to 1.01, ALP OR 0.86, 95% CI 0.

177 T levels <22 U/L as the referent, the middle ALT levels (>/=22 to <40 U/L) [odds ratio (OR) (95% conf

178 erogeneous telomere lengths observed in most ALT cancers.

179 Patients with new ALT elevations to >100 IU/L were seldom assessed for inc

180 a 16% increased odds of having above-normal ALT (95% CI: odds ratio: 1.02, 1.33%).

181 g/m(2) ), healthy non-NAFLD controls (normal ALT and BMI), or indeterminate.

182 groups: no NAFLD (n = 60); NAFLD with normal ALT (n = 165); and NAFLD with elevated ALT (n = 215).

183 hed for body mass index to those with normal ALT, had worse adipose tissue insulin resistance (ATIR;

184 M50 (rs738409) to assess the associations of ALT (U/L) with IHD, diabetes and other CVD risk factors

185 ed MR analysis to assess the associations of ALT (U/L) with IHD, diabetes and other CVD risk factors.

186 d to examine full-range risk associations of ALT levels with GDM.

187 plexes forming the nucleic acid component of ALT-associated PML bodies.

188 s and may facilitate clinical development of ALT detection assays and personalized treatment decision

189 ly+/-splenomegaly; (2)>6 months elevation of ALT (>1.5x upper limit of normal ULN); or (3) abnormal l

190 a lesser extent of postpartum elevations of ALT (P = 0.007), and a lower rate of ALT over five times

191 tension, thrombocytopenia, and elevations of ALT and AST, resulting in 0.3 mug/kg per day being deter

192 d lead to telomere clustering, a hallmark of ALT cancers.

193 daily dose >50 mg, an increased incidence of ALT elevations in clinical trials, immunoallergic clinic

194 ood function during NMP, perfusate levels of ALT and D-dimers were low (</=3500 ng/mL), whereas signi

195 The potential mechanism of ALT is homology-directed telomere synthesis, but molecul

196 Recent insights into the mechanisms of ALT are uncovering novel avenues to exploit vulnerabilit

197 We confirm observations of ALT increasing the risk of diabetes, but cannot exclude

198 verweight/obesity greatly enhanced the OR of ALT >/=22 U/L from 1.44 (1.23-1.69) to 3.46 (2.79-4.29)

199 o account for the perceptual organization of ALT and SYNC sequences and thus remains a viable model o

200 on-canonical function, we created a panel of ALT cells with recombinant expression of TERT and TERT v

201 ions of ALT (P = 0.007), and a lower rate of ALT over five times the upper limit of normal (1.64% ver

202 ch inhibitors may be useful for treatment of ALT-positive cancers.

203 ghly selective for cancer cells that rely on ALT, suggesting that such inhibitors may be useful for t

204 tics have such clear and large influences on ALTs, our data provide a key benchmark against which to

205 potranspiration may have large influences on ALTs.

206 avy alcohol consumption, elevated AST and/or ALT (<300 U/L), serum bilirubin >34 mumol/L, and elevate

207 cts, not by mediation effects of high AST or ALT.

208 ny cataract were not mediated by high AST or ALT.

209 owed <6 months by >/=1 additional NAT(s), or ALT, AST, and platelets <90 days, or any test ordered by

210 on, SMARCAL1 deficiency does not yield other ALT phenotypes such as elevated telomere recombination.

211 ST1, Ov-CAL-1, M3/M4, Ov-RAL-1, Ov-RAL-2, Ov-ALT-1, Ov-FBA-1, and Ov-B8.

212 Observationally in 19,925 participants ALT levels were strongly positively associated with self

213 ion of TERT and TERT variants: TERT-positive ALT cells showed higher tolerance to genotoxic insults c

214 -number changes persisted, and TERT-positive ALT cells surviving genotoxic events propagated through

215 gical abnormalities, surviving TERT-positive ALT cells were found to have gross chromosomal instabili

216 Genetically predicted ALT, ALP and GGT were not clearly associated with CAD/MI

217 ese sequences that, if they persist, promote ALT.

218 with a high fibrosis score (F2-3) and raised ALT were significantly higher in patients with FD than i

219 both 5% and 20% mFPA as a cut-off for raised ALT.

220 Thicker soil organic layers also reduced ALTs, though were less influential than moss thickness.

221 were excluded, these associations remained (ALT beta = -0.11, p = 0.0037; AST beta = -0.05, p = 0.03

222 ntially be used for deriving high-resolution ALTs in other remote areas similar to QTP, where only sp

223 Fat Equation', included age, fS-pIGFBP-1, S-ALT, waist-to-hip ratio, fP-Glucose and fS-Insulin (adju

224 better than a model without fS-pIGFBP-1 or S-ALT or S-AST alone.

225 on of plasma AST, salivary AST, and salivary ALT with uric acid level.

226 Serum ALT and total BA levels were significantly higher in tho

227 Serum ALT value, and hepatic thiobarbituric acid reactive subs

228 oups in HS (17.7% vs. 15.5%; P = 0.4), serum ALT (36 vs. 46 IU/L; P = 0.4), or CK-18 levels (175 vs.

229 opy number showed significantly higher serum ALT and triglyceride (P < 0.05).

230 A high WBC count, raised serum ALT, raised serum total bilirubin and a lack of endoscop

231 iants (P = 0.044) were associated with serum ALT levels, by interacting with each other, in that the

232 ion characteristics limiting thaw (shallower ALTs) were tree leaf area index (LAI), moss layer thickn

233 No shorter ALT isoforms were identified.

234 relationship with ALT remained significant (ALT beta = -0.08, p = 0.0400; AST beta = -0.03, p = 0.20

235 The results are compatible with those sparse ALT observations/estimations by traditional methods, whi

236 d awareness of NAFLD prevalence and stricter ALT cutoffs may ameliorate this problem.

237 In summary, ALT cells exhibit more telomere replication defects that

238 In summary, ALT joins PAN/nut1/T1.1 as a bona fide lncRNA of KSHV wi

239 Treatments targeting ALT may hold promise for a broadly applicable therapeuti

240 ase and alternative lengthening of telomere (ALT) mechanisms in vivo.

241 n of an alternative lengthening of telomere (ALT) pathway, but found no evidence of cell death, impai

242 hrough alternative lengthening of telomeres (ALT) display persistent sister telomere cohesion.

243 Alternative lengthening of telomeres (ALT) is a telomerase independent telomere maintenance me

244 Alternative lengthening of telomeres (ALT) is a telomerase-independent telomere maintenance me

245 Alternative lengthening of telomeres (ALT) necessitates homology-directed DNA repair to mainta

246 se the alternative lengthening of telomeres (ALT) pathway as their telomere maintenance mechanism.

247 ng the alternative lengthening of telomeres (ALT) pathway for telomere elongation, SMARCAL1 deficienc

248 or the alternative lengthening of telomeres (ALT) pathway to overcome replicative mortality.

249 ze the Alternative Lengthening of Telomeres (ALT) pathway.

250 endent alternative lengthening of telomeres (ALT) pathway.

251 ciated alternative lengthening of telomeres (ALT) pathway.

252 on the alternative lengthening of telomeres (ALT), a recombination-based mechanism for telomere-lengt

253 K18 predicted acute liver injury better than ALT alone (cfNRI 1.95 [95% CI 1.87-2.03], p<0.0001 in th

254 miR-122-5p was more sensitive than ALT for reporting liver injury at hospital presentation,

255 These methods confirm that ALT initiates at positions 120739/121012 and encodes a s

256 telomerase positive cells, we observed that ALT cells possess excessively long telomeric overhangs d

257 t-derived ALT human cell lines, we show that ALT cells harbor more fragile telomeres representing tel

258 s using Mendelian randomization suggest that ALT reduces the risk of IHD, probably through reducing t

259 ation, or cell cycle arrest, suggesting that ALT activation may prevent oxidative damage from reachin

260 The ALT pathway is expressed in stem cells and basal cells i

261 The ALT pathway is suppressed in primary, but not metastatic

262 in long-term surviving clones acquiring the ALT pathway but at a very low frequency.

263 In addition, the ALT activity in PD-1(-/-) mice cotreated with anti-CTLA4

264 ruplexes, or R-loop formation facilitate the ALT pathway and lead to telomere clustering, a hallmark

265 Patients who experience flares in the ALT level are also more likely to progress.

266 Prevalence of TERT reactivation over the ALT mechanism was linked to secondary TERT function unre

267 teractions can be explored for targeting the ALT cancers.

268 We propose that the ALT pathway preferentially occurs at telomeric lagging s

269 BRCA1, and BLM are actively recruited to the ALT telomeres that are experiencing replication stress a

270 f a novel fusion molecule, 2B8T2M, using the ALT-803 scaffold fused to four single chains of the tumo

271 eat transfer model of soils, we estimate the ALTs.

272 In the case study, the ALTs are ranging from 1.02 to 3.14 m and with an average

273 By comparing these ALT cells with parental telomerase positive cells, we ob

274 l method to estimate active layer thickness (ALT) over permafrost based on InSAR (Interferometric Syn

275 of thaw each summer (active-layer thickness; ALT), but a quantitative understanding of the relative i

276 Thus, ALT-803 can be modified as a functional scaffold for cre

277 ile site instability, and localizing SLX4 to ALT telomeres.

278 transaminase (AST) and alanine transaminase (ALT) levels, indicative of severe liver damage.

279 sterol, triglycerides, alanine transaminase (ALT), and aspartate transaminase (AST) were measured.

280 amyltransferase (GGT), alanine transaminase (ALT), fetuin-A, and the algorithm-based fatty liver inde

281 ts alanine and employs alanine transaminase (ALT), pyruvate oxidase (POx), and horseradish peroxidase

282 The antisense-to-latency transcript (ALT) lncRNA was discovered by genome-tiling microarray.

283 tics associated with persistent on-treatment ALT elevation (POAE), and its impact on treatment outcom

284 ctivation of the FA pathway does not trigger ALT, as FANCD2 depleted telomerase positive cells do not

285 notopic activity patterns was observed under ALT than under SYNC conditions, thus paralleling the per

286 of A and B tone responses was observed under ALT than under SYNC conditions, thus paralleling the per

287 zes a specialized replisome, which underlies ALT telomere maintenance.

288 with a blocking dose (50mg/kg) of unlabeled ALT-836.

289 is frequently lost in cancer cells that use ALT (alternative lengthening of telomeres) for telomere

290 Using ALT levels <22 U/L as the referent, the middle ALT level

291 affect the relative influence of C-NHEJ vs. ALT-EJ on rearrangement formation.

292 he most common grade 3-4 adverse events were ALT elevation (two [67%] of three) and rash (two [67%] o

293 on of the estimation of the InSAR pixel-wise ALTs.

294 obe annotated to SLC7A11 was associated with ALT after Bonferroni correction (1.0 x 10(-7)).

295 ve serum PFOA was positively associated with ALT levels (p for trend < 0.0001), indicating possible l

296 n abnormalities, a phenotype associated with ALT tumors.

297 atin-remodeling protein ATRX associates with ALT in cancers.

298 showed significant inverse associations with ALT (beta = -0.08, p = 0.0111), AST (beta = -0.05, p = 0

299 r insulin sensitivity, the relationship with ALT remained significant (ALT beta = -0.08, p = 0.0400;

300 We recruited 17359 Chinese women with ALT measured in their first trimester.